Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001
Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Kiefer J, Maitra A, Hidalgo M, Kumar R, Hlavacek W, Stites E, Posner R, Ramanathan R, Von Hoff D. Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001. Cancer Research 2012, 72: 3697-3697. DOI: 10.1158/1538-7445.am2012-3697.Peer-Reviewed Original ResearchComparative genomic hybridizationPhase II studyStudies of therapyMolecular profilingTreating metastatic pancreatic cancerK-rasPanel of xenograftsAneuploid tumour cell populationsMetastatic pancreatic cancerComparative genomic hybridization arrayAmerican Association for Cancer ResearchTherapeutic targetK-ras mutationsTumor cell populationGene expression microarray analysisExpression microarray analysisFocal ampliconsMetastatic lesionsMetastatic biopsiesC-kitGenomic hybridizationPancreatic cancerTumor nucleiHomozygous deletionDrug sensitivity